Outcome reporting from protocols of clinical trials of Coronavirus Disease 2019 (COVID-19): a review
Ruijin Qiu, Xuxu Wei, Mengzhu Zhao, Changming Zhong, Chen Zhao, Jiayuan Hu, Min Li, Ya Huang, Songjie Han, Tianmai He, Jing Chen, Hongcai Shang
doi: https://doi.org/10.1101/2020.03.04.20031401
Abstract
Objectives: To examine heterogeneity of outcomes in protocols of clinical trials of Coronavirus Disease 2019 (COVID-19) and to identify outcomes for prioritization in developing a core outcome set (COS) in this field. Design: This study is a review. Data sources: Databases of ICMJE-accepted clinical trial registry platform were searched on February 14, 2020. Eligibility Criteria: Randomized controlled trials (RCTs) and non-RCTs of COVID-19 were considered.Conditions of patients include common type, severe type or critical type. Interventions include traditional Chinese medicine (TCM) and Western medicine. We excluded trials that for discharged patients, psychological intervention and complications of COVID-19. Data extraction and synthesis: The general information and outcomes, outcome measurement instruments and measurement times were extracted.
*注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
